What is the clinical difference between a peptide blend and a peptide stack?

A peptide blend refers to two or more active peptides freeze-dried (co-lyophilized) together within the same vial by a 503A/503B compounding pharmacy. A peptide stack refers to administering individual compounds from separate vials on a coordinated schedule. Blends simplify administration but fix the ratio; stacks allow independent dose titration of each compound.

How do you calculate syringe draw units for co-lyophilized vials?

When two peptides are co-lyophilized (e.g. 5mg BPC-157 + 5mg TB-500 = 10mg total) and reconstituted with 2.0 mL bacteriostatic water, each compound is present at 2.5 mg/mL. Drawing 0.10 mL (10 units on a U-100 syringe) delivers 250 mcg of each compound simultaneously. Always calculate based on a single compound concentration since the ratio in the vial is fixed.

Can you combine two separately reconstituted peptides in one syringe?

Tandem drawing is common practice to avoid multiple injections. Requirements: both solutions must use bacteriostatic water as diluent, both should have compatible neutral pH (6.5-7.5), and the combined volume should be injected immediately - not stored pre-mixed in a plastic syringe barrel.

Why are GLP-1 compounds like Semaglutide co-formulated with B-vitamins?

503A compounding pharmacies co-formulate GLP-1 agonists with B-vitamins (B12 or B3) for two reasons: (1) Caloric restriction from incretin agonism causes fatigue and nausea - B-vitamins support energy metabolism and GI comfort. (2) Co-formulation with a vitamin creates a medically individualized prescription that satisfies 503A compounding requirements.

What are the storage requirements for reconstituted blend vials?

Reconstituted peptide blend vials must be refrigerated at 2-8 degrees C (36-46 degrees F), protected from light, and never frozen. The 0.9% benzyl alcohol preservative in bacteriostatic water maintains stability for 28-35 days.

What is the clinical difference between a peptide blend and a peptide stack?

A peptide blend refers to two or more active peptides freeze-dried (co-lyophilized) together within the same vial by a 503A/503B compounding pharmacy. A peptide stack refers to administering individual compounds from separate vials on a coordinated schedule. Blends simplify administration but fix the ratio; stacks allow independent dose titration of each compound.

How do you calculate syringe draw units for co-lyophilized vials?

When two peptides are co-lyophilized (e.g. 5mg BPC-157 + 5mg TB-500 = 10mg total) and reconstituted with 2.0 mL bacteriostatic water, each compound is present at 2.5 mg/mL. Drawing 0.10 mL (10 units on a U-100 syringe) delivers 250 mcg of each compound simultaneously. Always calculate based on a single compound concentration since the ratio in the vial is fixed.

Can you combine two separately reconstituted peptides in one syringe?

Tandem drawing is common practice to avoid multiple injections. Requirements: both solutions must use bacteriostatic water as diluent, both should have compatible neutral pH (6.5-7.5), and the combined volume should be injected immediately - not stored pre-mixed in a plastic syringe barrel.

Why are GLP-1 compounds like Semaglutide co-formulated with B-vitamins?

503A compounding pharmacies co-formulate GLP-1 agonists with B-vitamins (B12 or B3) for two reasons: (1) Caloric restriction from incretin agonism causes fatigue and nausea - B-vitamins support energy metabolism and GI comfort. (2) Co-formulation with a vitamin creates a medically individualized prescription that satisfies 503A compounding requirements.

What are the storage requirements for reconstituted blend vials?

Reconstituted peptide blend vials must be refrigerated at 2-8 degrees C (36-46 degrees F), protected from light, and never frozen. The 0.9% benzyl alcohol preservative in bacteriostatic water maintains stability for 28-35 days.

Clinical Reference Formulary · 2026

Multi-Compound Peptide Formulations & Stacks

Technical pharmacology, reconstitution ratios, syringe draw calculations, and clinical evidence for evidence-backed multi-peptide protocols.

Medical Review Board

Updated September 2026

7 of 7 protocols

503A Compounded StandardTissue Repair

BPC-157 + TB-500

Pentadecapeptide + Thymosin Beta-4 Fragment

Accelerated tendon, ligament, and gastrointestinal mucosal repair

Dosage Calculator

Compound A

BPC-157 (Body Protection Compound)

VEGF microvascular angiogenesis and localized collagen organization

Standard: 5.0 mg

Compound B

TB-500 (Thymosin Beta-4 Fragment)

G-to-F actin polymerization and systemic cellular migration

Standard: 5.0 mg or 10.0 mg

Pharmacological Synergy

BPC-157 drives localized capillary perfusion at the injury margin while TB-500 accelerates progenitor cell migration across the extracellular matrix. Together they address both angiogenesis and cellular scaffolding.

Standard Dosing

250-500 mcg BPC-157 + 250-500 mcg TB-500, once daily SubQ

Timing & Route

SubQ adjacent to injury site or abdominal adipose, 4-8 week cycle

Reconstitution

2.0 mL Bacteriostatic Water giving 2.5 mg/mL per compound

U-100 Draw

10 units (0.10 mL) on U-100 syringe = 250 mcg each compound

Documented Outcomes

Accelerated tendon and ligament tensile strength recovery
Gastric and intestinal mucosal integrity restoration
Systemic progenitor cell recruitment to injury sites
Reduction in post-exercise inflammatory markers

Applications: Tendon injuries, ligament sprains, GI inflammation, post-surgical recovery.

Caution in patients with active malignancy. VEGF upregulation may promote tumor angiogenesis. Contraindicated in pregnancy.

503A Compounded StandardGH Secretagogues

CJC-1295 + Ipamorelin

Modified GRF(1-29) + Selective GHS-R1a Agonist

Pulsatile growth hormone secretion enhancement for body composition optimization

Dosage Calculator

Compound A

CJC-1295 No-DAC (Mod GRF 1-29)

GHRH receptor agonism on somatotrophs

Standard: 2.0-5.0 mg

Compound B

Ipamorelin (Selective Ghrelin Mimetic)

GHS-R1a ghrelin receptor agonism on pituitary somatotrophs

Standard: 2.0-5.0 mg

Pharmacological Synergy

CJC-1295 primes pituitary somatotrophs via the GHRH receptor while Ipamorelin triggers a simultaneous GHS-R1a-mediated GH pulse. The dual-receptor activation creates synergistic amplified yet physiologically-pulsatile GH release.

Standard Dosing

100-200 mcg CJC-1295 + 100-200 mcg Ipamorelin, 2-3x daily SubQ

Timing & Route

Administer on empty stomach; optimal: pre-sleep + post-workout

Reconstitution

2.0 mL Bacteriostatic Water giving 2.5 mg/mL per compound

U-100 Draw

4 units (0.04 mL) = 100 mcg CJC-1295 + 100 mcg Ipamorelin

Documented Outcomes

Amplified pulsatile GH release maintaining physiological rhythm
Improved lean muscle mass retention and fat oxidation
Enhanced IGF-1 production and downstream anabolic signaling
Improved slow-wave sleep architecture and recovery metrics

Applications: Body recomposition, anti-aging GH optimization, recovery enhancement, sleep improvement.

Contraindicated in active malignancy. Somatotroph adenomas preclude use. Diabetic patients require glucose monitoring.

503A Compounded StandardGLP-1 and Metabolic

Semaglutide + Vitamin B12

GLP-1 Receptor Agonist + Cyanocobalamin

GLP-1 mediated weight management with B12 co-administration for nausea and energy mitigation

Dosage Calculator

Compound A

Semaglutide (GLP-1 Receptor Agonist)

GLP-1R agonism for incretin effect, satiety signaling, beta-cell stimulation

Standard: 2.5-5.0 mg per vial

Compound B

Cyanocobalamin (Vitamin B12)

Methionine synthase cofactor for methylation, neurological function, energy metabolism

Standard: 1000 mcg

Pharmacological Synergy

Semaglutide GLP-1 agonism induces caloric restriction and nausea as a primary adverse effect. Cyanocobalamin supports mitochondrial energy metabolism and may reduce nausea severity while addressing B12 depletion risk.

Standard Dosing

Semaglutide titrated per protocol 0.25 to 2.4 mg/week; B12 co-administered weekly

Timing & Route

Weekly SubQ injection, rotate sites (abdomen, thigh, upper arm)

Reconstitution

Pre-mixed by 503A pharmacy; standard multi-dose bacteriostatic vial

U-100 Draw

Per prescriber titration protocol; see compounding pharmacy label

Documented Outcomes

Mean 15-17% total body weight reduction over 68 weeks (STEP trial series)
Reduction in HbA1c and fasting glucose in T2DM patients
Improved satiety signaling and reduced caloric intake
B12 co-administration may reduce nausea incidence and fatigue

Applications: Obesity (BMI 30+), T2DM, metabolic syndrome, weight management.

Personal or family history of medullary thyroid carcinoma (MTC) or MEN2. Acute pancreatitis history. Contraindicated in pregnancy.

503A Compounded StandardGLP-1 and Metabolic

Tirzepatide + Niacinamide

Dual GIP/GLP-1 Receptor Agonist + Vitamin B3

Dual incretin agonist weight management with niacinamide for hepatic lipid support

Dosage Calculator

Compound A

Tirzepatide (Dual GIP/GLP-1 Agonist)

Simultaneous GIPR and GLP-1R dual agonism for superior weight loss vs. mono-agonists

Standard: 2.5-15 mg per vial

Compound B

Niacinamide (Nicotinamide / Vitamin B3)

NAD+ precursor supporting hepatic lipid metabolism and cellular energy

Standard: 50-100 mg

Pharmacological Synergy

Tirzepatide dual incretin agonism produces superior weight reduction vs. GLP-1 mono-agonists. Niacinamide as NAD+ precursor supports hepatic lipid oxidation pathway required to safely process mobilized adipose stores.

Standard Dosing

Tirzepatide titrated 2.5 to 15 mg/week SubQ; Niacinamide co-dosed

Timing & Route

Weekly SubQ injection; same day each week, dose site rotation required

Reconstitution

Formulated by 503A pharmacy per prescribing physician specification

U-100 Draw

Per prescriber protocol; see compounded vial concentration label

Documented Outcomes

Mean 22.5% total body weight reduction at 72 weeks (SURMOUNT-1)
Superior HbA1c reduction vs. semaglutide in SURPASS-2 head-to-head trial
Significant improvement in triglycerides and non-HDL cholesterol
Niacinamide supports hepatic lipid clearance during adipose mobilization

Applications: Class II/III obesity, T2DM with cardiovascular risk, metabolic syndrome with hepatic involvement.

Same MTC/MEN2 contraindication as all GLP-1 agonists. Pancreatitis history. Avoid in severe renal or hepatic impairment without specialist oversight.

503A Compounded StandardCellular Longevity

NAD+ + Glutathione

Nicotinamide Adenine Dinucleotide + Tripeptide Antioxidant

Mitochondrial redox restoration and cellular anti-aging metabolic support

Compound A

NAD+ (Nicotinamide Adenine Dinucleotide)

Sirtuin activation, PARP repair, mitochondrial electron transport chain redox

Standard: 100-500 mg IV or SubQ

Compound B

Glutathione (GSH)

ROS scavenging, xenobiotic detoxification, recycling of oxidized vitamins

Standard: 200-600 mg IV or SubQ

Pharmacological Synergy

NAD+ replenishment restores the cellular oxidation-reduction ratio critical for mitochondrial function, while glutathione acts as the primary cytosolic antioxidant buffer scavenging ROS generated during increased mitochondrial respiration.

Standard Dosing

IV infusion: weekly; SubQ: 100 mg NAD+ + 200 mg GSH daily or 3x/week

Timing & Route

IV: slow infusion over 60-120 min; SubQ: morning injection

Reconstitution

IV: in 250 mL normal saline; SubQ: reconstitute in 1.0-2.0 mL sterile water

U-100 Draw

SubQ: per prescriber protocol (concentration varies by compounding pharmacy)

Documented Outcomes

Mitochondrial respiration efficiency restoration and ATP production
Sirtuin-1/3 activation and associated epigenetic longevity signaling
Reduction in biomarkers of oxidative stress (8-OHdG, F2-isoprostanes)
Improved cellular detoxification capacity and hepatic Phase II metabolism

Applications: Anti-aging longevity protocols, post-COVID fatigue, neurodegenerative support, liver detoxification.

IV NAD+ infusion can cause transient chest tightness, flushing, and nausea if infused too rapidly. Glutathione is safe at standard doses; caution in patients with cystinuria.

Preclinical ResearchNeurology

Semax + Selank

ACTH(4-10) Heptapeptide + Tuftsin Analogue

Anxiolytic-nootropic combination for cognitive enhancement without sedation

Compound A

Semax (ACTH 4-10 Heptapeptide)

BDNF/NGF upregulation, dopaminergic/serotonergic modulation

Standard: 300-600 mcg

Compound B

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro)

IL-6 modulation, GABA-A potentiation, enkephalin-ase inhibition

Standard: 250-500 mcg

Pharmacological Synergy

Semax drives BDNF and NGF upregulation enhancing cognitive processing and neurogenesis, while Selank reduces anxiety via GABA-A potentiation without the sedation or dependency risk of benzodiazepines.

Standard Dosing

300 mcg Semax + 250 mcg Selank 1-2x daily (intranasal or SubQ)

Timing & Route

Morning administration for cognitive enhancement; divided dose for anxiety reduction

Reconstitution

1.0 mL per vial; standard concentration 0.1% (1mg/mL)

U-100 Draw

Intranasal: 2 drops per nostril; SubQ: 3 units (0.03 mL) = 300 mcg Semax

Documented Outcomes

Significant BDNF upregulation and synaptic plasticity enhancement
Anxiolytic efficacy without sedation, tolerance, or dependency potential
Improved working memory and executive function metrics
Reduced cortisol awakening response and stress reactivity markers

Applications: Cognitive performance, anxiety management, neuroprotection, stress resilience research.

Research Use Only outside Russia/Ukraine. Data on drug-drug interactions is limited. Caution with concomitant GABAergic agents.

FDA-Approved ActiveEndocrine and Sexual Health

PT-141 + Oxytocin

Bremelanotide (MC3/MC4 Agonist) + Neurohypophysial Nonapeptide

Central mechanism desire disorder and sexual dysfunction via CNS pathway

Compound A

PT-141 / Bremelanotide

MC3R/MC4R melanocortin agonism in hypothalamic desire circuits

Standard: 1.75 mg

Compound B

Oxytocin (Nonapeptide Neuropeptide)

Limbic dopamine modulation, hypothalamic bonding and intimacy signaling

Standard: 10-40 IU intranasal

Pharmacological Synergy

PT-141 activates central MC3/MC4 receptors to initiate desire signaling independently of vascular mechanisms, while oxytocin enhances limbic emotional bonding and intimacy responsiveness.

Standard Dosing

1.75 mg PT-141 SubQ 45 min pre-activity; 40 IU oxytocin intranasal 20 min pre-activity

Timing & Route

PT-141: SubQ injection 45-90 min before activity; Oxytocin: intranasal 20-30 min before

Reconstitution

PT-141: 1.0 mL sterile water; Oxytocin: intranasal spray formulation (pharmacy)

U-100 Draw

PT-141: 17.5 units (0.175 mL) at 10 mg/mL solution = 1.75 mg dose

Documented Outcomes

FDA-validated efficacy for hypoactive sexual desire disorder (HSDD)
Central mechanism effective where PDE-5 inhibitors have failed
Oxytocin enhances emotional connection and relational intimacy
Applicable for both male and female desire dysfunction

Applications: HSDD, central erectile dysfunction, desire enhancement, intimacy optimization.

PT-141 causes transient blood pressure elevation. Contraindicated in uncontrolled hypertension or cardiovascular disease. Limit to 8 doses/month. Oxytocin: caution with antidiuretics.

Stack Safety & Synergy Checker

Check for receptor conflicts and safety warnings before combining compounds

Stack Synergy & Safety Checker

Select up to 3 compounds to check for synergistic effects, receptor competition, or dangerous contraindications.

Select Compounds (Max 3)

Select at least two compounds above to see interaction results.

Co-Lyophilized Vial Reconstitution Reference

When preparing co-lyophilized vials containing two distinct peptides in fixed ratios, dose calculations must reflect individual compound concentration - not total powder mass.

Add Diluent

Introduce 2.0 mL of bacteriostatic 0.9% benzyl alcohol water slowly down the vial wall. Do not agitate - gently swirl.

Calculate Concentration

5 mg BPC-157 / 2.0 mL = 2.5 mg/mL (each compound). Per 0.1 mL drawn = 250 mcg of each compound.

Draw on U-100

Draw to the 10-unit mark (0.10 mL) = 250 mcg BPC-157 + 250 mcg TB-500 simultaneously.

Need calculations for custom vial sizes or individual peptide dosing?Open Reconstitution Calculators

Verified Clinical Network

Connect with Licensed Peptide & GLP-1 Physicians

Browse our verified directory of 4,700+ state-licensed peptide therapy, GLP-1, and hormone optimization practices across 46 states.

Browse Verified Clinics

Frequently Asked Questions

: A peptide blend refers to two or more active peptides freeze-dried (co-lyophilized) together within the same vial by a 503A/503B compounding pharmacy. A peptide stack refers to administering individual compounds from separate vials on a coordinated schedule. Blends simplify administration but fix the ratio; stacks allow independent dose titration of each compound.
: When two peptides are co-lyophilized (e.g. 5mg BPC-157 + 5mg TB-500 = 10mg total) and reconstituted with 2.0 mL bacteriostatic water, each compound is present at 2.5 mg/mL. Drawing 0.10 mL (10 units on a U-100 syringe) delivers 250 mcg of each compound simultaneously. Always calculate based on a single compound concentration since the ratio in the vial is fixed.
: Tandem drawing is common practice to avoid multiple injections. Requirements: both solutions must use bacteriostatic water as diluent, both should have compatible neutral pH (6.5-7.5), and the combined volume should be injected immediately - not stored pre-mixed in a plastic syringe barrel.
: 503A compounding pharmacies co-formulate GLP-1 agonists with B-vitamins (B12 or B3) for two reasons: (1) Caloric restriction from incretin agonism causes fatigue and nausea - B-vitamins support energy metabolism and GI comfort. (2) Co-formulation with a vitamin creates a medically individualized prescription that satisfies 503A compounding requirements.
: Reconstituted peptide blend vials must be refrigerated at 2-8 degrees C (36-46 degrees F), protected from light, and never frozen. The 0.9% benzyl alcohol preservative in bacteriostatic water maintains stability for 28-35 days.

Educational & Research Notice: The information on this page is strictly for educational, scientific reference, and harm-reduction purposes. OnePeptideShip does not manufacture, distribute, or prescribe pharmaceutical substances. Some compounds referenced are FDA-approved prescription therapeutics; others are Research Use Only (RUO) agents. All therapeutic interventions require consultation with a licensed medical physician.